Fulcrum Therapeutics’ (FULC) “Neutral” Rating Reaffirmed at HC Wainwright

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 8.11% from the stock’s previous close.

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $3.70 on Wednesday. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The stock has a market cap of $199.57 million, a P/E ratio of -11.94 and a beta of 2.03. The stock has a 50 day moving average of $4.15 and a 200 day moving average of $4.62.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. raised its stake in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. Mariner LLC purchased a new position in Fulcrum Therapeutics in the 4th quarter valued at $78,000. Walleye Capital LLC acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth $59,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Fulcrum Therapeutics during the third quarter worth $62,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.